Covered recipient · General Payments record
AMIT BHANVADIA
Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2022 · Entire year
$1,186.58
56 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2022 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $1,186.58 | 56 |
By paying entity
PY2022 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $432.17 | 17 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $202.67 | 10 |
| Celgene Corporation | $146.08 | 9 |
| Nestle HealthCare Nutrition Inc. | $79.45 | 4 |
| QOL Medical, LLC | $73.47 | 4 |
| Gilead Sciences, Inc. | $56.82 | 2 |
| Ardelyx, Inc. | $52.84 | 2 |
| RedHill Biopharma Inc. | $38.06 | 2 |
| INTERCEPT PHARMACEUTICALS, INC. | $22.40 | 1 |
| PFIZER INC. | $22.02 | 1 |
| Janssen Biotech, Inc. | $18.59 | 1 |
| Ironwood Pharmaceuticals, Inc | $17.02 | 1 |
| Takeda Pharmaceuticals U.S.A., Inc. | $15.90 | 1 |
| INTRA-SANA LABORATORIES | $9.09 | 1 |
Page 2 of 2; records 51–56 of 56 matching records. This page contains 6 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
AMIT BHANVADIA
NPI 1861751083 · CMS profile ID 6575304
Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology
ANAHEIM, CA
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 2; records 51–56 of 56 matching records. This page contains 6 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1861751083?year=2022&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- AMIT BHANVADIA, NPI 1861751083, CMS profile ID 6575304. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–56 of 56 matching records. This page contains 6 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1861751083?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
- APA 7
- IndustryPayments. (2026). AMIT BHANVADIA, NPI 1861751083, CMS profile ID 6575304. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–56 of 56 matching records. This page contains 6 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1861751083?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
- Bluebook
- AMIT BHANVADIA, NPI 1861751083, CMS profile ID 6575304, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–56 of 56 matching records. This page contains 6 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1861751083?year=2022&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2022
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30
56 matching records · $1,186.58 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–56 of 56.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Nestle HealthCare Nutrition Inc. | $19.52 | 01/25/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 902769429 | CMS |
| ABBVIE INC. | $24.85 | 01/20/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 890607453 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $15.90 | 01/12/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 955594575 | CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $16.75 | 01/05/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 959844110 | CMS |
| ABBVIE INC. | $16.42 | 01/04/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 890607451 | CMS |
| QOL Medical, LLC | $15.57 | 01/03/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 904147817 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $388.40 | 1 |
| PY2025 | Principal investigator | $654,493.09 | 232 |
| PY2024 | Recipient | $16,260.55 | 2 |
| PY2024 | Principal investigator | $593,611.97 | 110 |
| PY2023 | Principal investigator | $386,555.18 | 106 |
| PY2022 | Principal investigator | $42,522.20 | 20 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
233 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Janssen Research & Development, LLC | $624.00 | 12/29/2025 | Non-covered Recipient Entity CLINNOVA RESEARCH SOLUTIONS CORPORA | ??A Phase 2b Multicenter, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Moderately to Severely Active Ulcerative Colitis?. ??Efficacy and Safety of JNJ-77242113 in Participants with Moderately to Severely Active Ulcerative Colitis? | No dispute reported | 06/30/2026 | 1175421726 |
| Principal investigator 1 | Janssen Research & Development, LLC | $8,181.00 | 12/25/2025 | Non-covered Recipient Entity CLINNOVA RESEARCH SOLUTIONS, CORPOR | A Phase 3 Randomized, Double-blind, Placebo-Controlled, Parallel Group, Multicenter Protocol in Adults with an Open Label Study in Adolescents to Evaluate the Efficacy and Safety of Induction and Maintenance Therapy with Icotrokinra in Participants With Moderately to Severely Active Ulcerative Colitis ICONIC-UC | No dispute reported | 06/30/2026 | 1175421762 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $798.20 | 12/19/2025 | Non-covered Recipient Entity Clinnova | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220695587 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $798.20 | 12/19/2025 | Non-covered Recipient Entity Clinnova | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220695589 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $287.30 | 12/19/2025 | Non-covered Recipient Entity Clinnova | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220695591 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,700.40 | 12/19/2025 | Non-covered Recipient Entity Clinnova | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220695647 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $14,474.20 | 12/19/2025 | Non-covered Recipient Entity Clinnova | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220695649 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.96 | 12/17/2025 | Non-covered Recipient Entity Clinnova | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220695607 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $255.50 | 12/17/2025 | Non-covered Recipient Entity Clinnova | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220695609 |
| Principal investigator 1 | Janssen Research & Development, LLC | $28,036.00 | 12/15/2025 | Non-covered Recipient Entity CLINNOVA RESEARCH SOLUTIONS, CORPOR | A Phase 3 Randomized, Double-blind, Placebo-Controlled, Parallel Group, Multicenter Protocol in Adults with an Open Label Study in Adolescents to Evaluate the Efficacy and Safety of Induction and Maintenance Therapy with Icotrokinra in Participants With Moderately to Severely Active Ulcerative Colitis ICONIC-UC | No dispute reported | 06/30/2026 | 1175421755 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $475.00 | 12/12/2025 | Non-covered Recipient Entity CLINNOVA RESEARCH SOLUTIONS | A PHASE 4 STUDY EVALUATING REAL-WORLD USE OF CDPATH?, A CROHN'S DISEASE RISK PREDICTION TOOL | No dispute reported | 06/30/2026 | 1223289650 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,171.30 | 12/11/2025 | Non-covered Recipient Entity CLINNOVA RESEARCH SOLUTIONS CORPORATION | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184274614 |
| Principal investigator 1 | ABBVIE INC. | $2,665.00 | 12/04/2025 | Non-covered Recipient Entity CLINNOVA RESEARCH SOLUTIONS | A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease | No dispute reported | 06/30/2026 | 1202527230 |
| Principal investigator 1 | Janssen Research & Development, LLC | $28,091.00 | 11/25/2025 | Non-covered Recipient Entity CLINNOVA RESEARCH SOLUTIONS, CORPOR | A Phase 3 Randomized, Double-blind, Placebo-Controlled, Parallel Group, Multicenter Protocol in Adults with an Open Label Study in Adolescents to Evaluate the Efficacy and Safety of Induction and Maintenance Therapy with Icotrokinra in Participants With Moderately to Severely Active Ulcerative Colitis ICONIC-UC | No dispute reported | 06/30/2026 | 1175421768 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $163.24 | 11/19/2025 | Non-covered Recipient Entity Clinnova | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220695599 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $19.98 | 11/19/2025 | Non-covered Recipient Entity Clinnova | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220695601 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $401.50 | 11/19/2025 | Non-covered Recipient Entity Clinnova | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220695603 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2.00 | 11/19/2025 | Non-covered Recipient Entity Clinnova | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220695605 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $99.90 | 11/19/2025 | Non-covered Recipient Entity Clinnova | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220695655 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $292.00 | 11/19/2025 | Non-covered Recipient Entity Clinnova | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220695657 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $8.00 | 11/19/2025 | Non-covered Recipient Entity Clinnova | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220695659 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,171.30 | 11/14/2025 | Non-covered Recipient Entity CLINNOVA RESEARCH SOLUTIONS CORPORATION | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184261325 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,581.00 | 11/07/2025 | Non-covered Recipient Entity CLINNOVA RESEARCH SOLUTIONS CORPORATION | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184258959 |
| Recipient | Eli Lilly and Company | $388.40 | 11/04/2025 | Covered Recipient Physician | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROLLED STUDY OF LY4268989 (MORF-057) CO-ADMINISTERED WITH MIRIKIZUMAB IN ADULTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS | No dispute reported | 06/30/2026 | 1187872067 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,728.00 | 10/31/2025 | Non-covered Recipient Entity CLINNOVA RESEARCH SOLUTIONS CORPORA | ??A Phase 2b Multicenter, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Moderately to Severely Active Ulcerative Colitis?. ??Efficacy and Safety of JNJ-77242113 in Participants with Moderately to Severely Active Ulcerative Colitis? | No dispute reported | 06/30/2026 | 1175421678 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,447.00 | 10/29/2025 | Non-covered Recipient Entity Clinnova Rsrch Solutions Corp. | A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease (GRAVITI) | No dispute reported | 06/30/2026 | 1175170769 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $99.90 | 10/27/2025 | Non-covered Recipient Entity Clinnova | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220695593 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $328.50 | 10/27/2025 | Non-covered Recipient Entity Clinnova | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220695595 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $7.00 | 10/27/2025 | Non-covered Recipient Entity Clinnova | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220695597 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,286.70 | 10/27/2025 | Non-covered Recipient Entity Clinnova | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220695643 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $14,474.20 | 10/27/2025 | Non-covered Recipient Entity Clinnova | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220695645 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $19.98 | 10/27/2025 | Non-covered Recipient Entity Clinnova | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220695651 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $255.50 | 10/27/2025 | Non-covered Recipient Entity Clinnova | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220695653 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,230.00 | 10/27/2025 | Non-covered Recipient Entity Clinnova Rsrch Solutions Corp. | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175170420 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,359.00 | 10/27/2025 | Non-covered Recipient Entity Clinnova Rsrch Solutions Corp. | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175170449 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,359.00 | 10/27/2025 | Non-covered Recipient Entity Clinnova Rsrch Solutions Corp. | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175170493 |
| Principal investigator 1 | Janssen Research & Development, LLC | $184.00 | 10/27/2025 | Non-covered Recipient Entity Clinnova Rsrch Solutions Corp. | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175170528 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,602.00 | 10/27/2025 | Non-covered Recipient Entity Clinnova Rsrch Solutions Corp. | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175170574 |
| Principal investigator 1 | Janssen Research & Development, LLC | $184.00 | 10/27/2025 | Non-covered Recipient Entity Clinnova Rsrch Solutions Corp. | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175170607 |
| Principal investigator 1 | Janssen Research & Development, LLC | $184.00 | 10/27/2025 | Non-covered Recipient Entity Clinnova Rsrch Solutions Corp. | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175170616 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,230.00 | 10/27/2025 | Non-covered Recipient Entity Clinnova Rsrch Solutions Corp. | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175170789 |
| Principal investigator 1 | Janssen Research & Development, LLC | $100.00 | 10/23/2025 | Non-covered Recipient Entity CLINNOVA RESEARCH SOLUTIONS CORPORA | ??A Phase 2b Multicenter, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Moderately to Severely Active Ulcerative Colitis?. ??Efficacy and Safety of JNJ-77242113 in Participants with Moderately to Severely Active Ulcerative Colitis? | No dispute reported | 06/30/2026 | 1175421721 |
| Principal investigator 1 | Janssen Research & Development, LLC | $50.00 | 10/20/2025 | Non-covered Recipient Entity CLINNOVA RESEARCH SOLUTIONS CORPORA | ??A Phase 2b Multicenter, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Moderately to Severely Active Ulcerative Colitis?. ??Efficacy and Safety of JNJ-77242113 in Participants with Moderately to Severely Active Ulcerative Colitis? | No dispute reported | 06/30/2026 | 1175421690 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $155.00 | 10/16/2025 | Non-covered Recipient Entity CLINNOVA RESEARCH SOLUTIONS CORPORATION | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184250665 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $45.00 | 10/16/2025 | Non-covered Recipient Entity CLINNOVA RESEARCH SOLUTIONS CORPORATION | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184250667 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $155.00 | 10/16/2025 | Non-covered Recipient Entity CLINNOVA RESEARCH SOLUTIONS CORPORATION | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184250669 |
| Principal investigator 1 | Bausch Health US, LLC | $902.50 | 09/30/2025 | Non-covered Recipient Entity CLINNOVA RESEARCH SOLUTIONS | A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis | No dispute reported | 06/30/2026 | 1224837506 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $525.20 | 09/29/2025 | Non-covered Recipient Entity Clinnova | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220695639 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,700.40 | 09/29/2025 | Non-covered Recipient Entity Clinnova | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220695641 |
| Principal investigator 1 | Janssen Research & Development, LLC | $18,107.00 | 09/29/2025 | Non-covered Recipient Entity CLINNOVA RESEARCH SOLUTIONS CORPORA TION | ??A Phase 2b Multicenter, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Moderately to Severely Active Ulcerative Colitis?. ??Efficacy and Safety of JNJ-77242113 in Participants | No dispute reported | 06/30/2026 | 1175421674 |
| Principal investigator 1 | Bausch Health US, LLC | $1,396.14 | 09/24/2025 | Non-covered Recipient Entity CLINNOVA RESEARCH SOLUTIONS | A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis | No dispute reported | 06/30/2026 | 1224837499 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $146.00 | 09/24/2025 | Non-covered Recipient Entity Clinnova | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220695585 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $19.98 | 09/24/2025 | Non-covered Recipient Entity Clinnova | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220695637 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,048.00 | 09/17/2025 | Non-covered Recipient Entity Clinnova Rsrch Solutions Corp. | A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease (GRAVITI) | No dispute reported | 06/30/2026 | 1175170536 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,048.00 | 09/17/2025 | Non-covered Recipient Entity Clinnova Rsrch Solutions Corp. | A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease (GRAVITI) | No dispute reported | 06/30/2026 | 1175170551 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,048.00 | 09/17/2025 | Non-covered Recipient Entity Clinnova Rsrch Solutions Corp. | A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease (GRAVITI) | No dispute reported | 06/30/2026 | 1175170648 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,048.00 | 09/17/2025 | Non-covered Recipient Entity Clinnova Rsrch Solutions Corp. | A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease (GRAVITI) | No dispute reported | 06/30/2026 | 1175170655 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,447.00 | 09/17/2025 | Non-covered Recipient Entity Clinnova Rsrch Solutions Corp. | A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease (GRAVITI) | No dispute reported | 06/30/2026 | 1175170740 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,447.00 | 09/17/2025 | Non-covered Recipient Entity Clinnova Rsrch Solutions Corp. | A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease (GRAVITI) | No dispute reported | 06/30/2026 | 1175170761 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,171.30 | 09/12/2025 | Non-covered Recipient Entity CLINNOVA RESEARCH SOLUTIONS CORPORATION | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184236570 |
| Principal investigator 1 | Bausch Health US, LLC | $1,619.59 | 09/11/2025 | Non-covered Recipient Entity CLINNOVA RESEARCH SOLUTIONS | A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis | No dispute reported | 06/30/2026 | 1224837503 |
| Principal investigator 1 | Janssen Research & Development, LLC | $50.00 | 09/08/2025 | Non-covered Recipient Entity CLINNOVA RESEARCH SOLUTIONS CORPORA TION | ??A Phase 2b Multicenter, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Moderately to Severely Active Ulcerative Colitis?. ??Efficacy and Safety of JNJ-77242113 in Participants | No dispute reported | 06/30/2026 | 1175421739 |
| Principal investigator 1 | ABBVIE INC. | $7,931.30 | 09/05/2025 | Non-covered Recipient Entity CLINNOVA RESEARCH SOLUTIONS | A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease | No dispute reported | 06/30/2026 | 1202510160 |
| Principal investigator 1 | Janssen Research & Development, LLC | $7,654.00 | 09/05/2025 | Non-covered Recipient Entity CLINNOVA RESEARCH SOLUTIONS CORPORA TION | ??A Phase 2b Multicenter, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Moderately to Severely Active Ulcerative Colitis?. ??Efficacy and Safety of JNJ-77242113 in Participants | No dispute reported | 06/30/2026 | 1175421694 |
| Principal investigator 1 | ABBVIE INC. | $5,330.00 | 09/04/2025 | Non-covered Recipient Entity CLINNOVA RESEARCH SOLUTIONS | A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease | No dispute reported | 06/30/2026 | 1202509892 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $148.00 | 08/26/2025 | Non-covered Recipient Entity Clinnova | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220695569 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $69.96 | 08/26/2025 | Non-covered Recipient Entity Clinnova | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220695571 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $159.84 | 08/26/2025 | Non-covered Recipient Entity Clinnova | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220695573 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,058.50 | 08/26/2025 | Non-covered Recipient Entity Clinnova | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220695575 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $252.20 | 08/26/2025 | Non-covered Recipient Entity Clinnova | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220695577 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $58.62 | 08/26/2025 | Non-covered Recipient Entity Clinnova | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220695579 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $12.60 | 08/26/2025 | Non-covered Recipient Entity Clinnova | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220695581 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $10.00 | 08/26/2025 | Non-covered Recipient Entity Clinnova | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220695583 |
| Principal investigator 1 | ABBVIE INC. | $5,265.00 | 08/06/2025 | Non-covered Recipient Entity CLINNOVA RESEARCH SOLUTIONS | A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease | No dispute reported | 06/30/2026 | 1202502725 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $90.00 | 08/04/2025 | Non-covered Recipient Entity Clinnova | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220695557 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $124.00 | 08/04/2025 | Non-covered Recipient Entity Clinnova | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220695559 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $40.00 | 08/04/2025 | Non-covered Recipient Entity Clinnova | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220695561 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $49.00 | 08/04/2025 | Non-covered Recipient Entity Clinnova | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220695563 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,128.00 | 07/31/2025 | Non-covered Recipient Entity CLINNOVA RESEARCH SOLUTIONS CORPORA TION | ??A Phase 2b Multicenter, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Moderately to Severely Active Ulcerative Colitis?. ??Efficacy and Safety of JNJ-77242113 in Participants | No dispute reported | 06/30/2026 | 1175421667 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $155.00 | 07/31/2025 | Non-covered Recipient Entity CLINNOVA RESEARCH SOLUTIONS CORPORATION | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184222830 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $14,474.20 | 07/30/2025 | Non-covered Recipient Entity Clinnova | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220695627 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $525.20 | 07/30/2025 | Non-covered Recipient Entity Clinnova | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220695629 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,992.90 | 07/30/2025 | Non-covered Recipient Entity Clinnova | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220695631 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $148.00 | 07/28/2025 | Non-covered Recipient Entity Clinnova | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220695565 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $139.86 | 07/28/2025 | Non-covered Recipient Entity Clinnova | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220695567 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $119.88 | 07/28/2025 | Non-covered Recipient Entity Clinnova | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220695633 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $109.50 | 07/28/2025 | Non-covered Recipient Entity Clinnova | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220695635 |
| Principal investigator 1 | Janssen Research & Development, LLC | $184.00 | 07/28/2025 | Non-covered Recipient Entity Clinnova Rsrch Solutions Corp. | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175170405 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,602.00 | 07/28/2025 | Non-covered Recipient Entity Clinnova Rsrch Solutions Corp. | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175170482 |
| Principal investigator 1 | Janssen Research & Development, LLC | $184.00 | 07/28/2025 | Non-covered Recipient Entity Clinnova Rsrch Solutions Corp. | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175170587 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,955.00 | 07/28/2025 | Non-covered Recipient Entity Clinnova Rsrch Solutions Corp. | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175170595 |
| Principal investigator 1 | Janssen Research & Development, LLC | $184.00 | 07/28/2025 | Non-covered Recipient Entity Clinnova Rsrch Solutions Corp. | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175170663 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,359.00 | 07/28/2025 | Non-covered Recipient Entity Clinnova Rsrch Solutions Corp. | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175170700 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,602.00 | 07/28/2025 | Non-covered Recipient Entity Clinnova Rsrch Solutions Corp. | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175170714 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $75.00 | 07/23/2025 | Non-covered Recipient Entity Clinnova | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220695553 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $74.50 | 07/23/2025 | Non-covered Recipient Entity Clinnova | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220695555 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,623.10 | 07/22/2025 | Non-covered Recipient Entity CLINNOVA RESEARCH SOLUTIONS CORPORATION | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184217759 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,412.20 | 07/16/2025 | Non-covered Recipient Entity Clinnova | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220695545 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,282.20 | 07/16/2025 | Non-covered Recipient Entity Clinnova | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220695547 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $13,699.40 | 07/16/2025 | Non-covered Recipient Entity Clinnova | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220695549 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,412.20 | 07/16/2025 | Non-covered Recipient Entity Clinnova | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220695551 |
| Principal investigator 1 | Janssen Research & Development, LLC | $75.00 | 07/10/2025 | Non-covered Recipient Entity CLINNOVA RESEARCH SOLUTIONS CORPORA TION | ??A Phase 2b Multicenter, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Moderately to Severely Active Ulcerative Colitis?. ??Efficacy and Safety of JNJ-77242113 in Participants | No dispute reported | 06/30/2026 | 1175421708 |
| Principal investigator 1 | ABBVIE INC. | $7,931.30 | 07/09/2025 | Non-covered Recipient Entity CLINNOVA RESEARCH SOLUTIONS | A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease | No dispute reported | 06/30/2026 | 1202497634 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,171.30 | 07/04/2025 | Non-covered Recipient Entity CLINNOVA RESEARCH SOLUTIONS CORPORATION | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184212847 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $175.00 | 07/04/2025 | Non-covered Recipient Entity CLINNOVA RESEARCH SOLUTIONS CORPORATION | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184212849 |
| Principal investigator 1 | ABBVIE INC. | $6,045.00 | 07/02/2025 | Non-covered Recipient Entity CLINNOVA RESEARCH SOLUTIONS | A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease | No dispute reported | 06/30/2026 | 1202494957 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $15,973.10 | 06/30/2025 | Non-covered Recipient Entity Clinnova | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220695477 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $798.20 | 06/30/2025 | Non-covered Recipient Entity Clinnova | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220695479 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,238.30 | 06/30/2025 | Non-covered Recipient Entity Clinnova | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220695481 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $798.20 | 06/30/2025 | Non-covered Recipient Entity Clinnova | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220695483 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $798.20 | 06/30/2025 | Non-covered Recipient Entity Clinnova | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220695485 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $11,359.40 | 06/30/2025 | Non-covered Recipient Entity Clinnova | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220695487 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,470.00 | 06/30/2025 | Non-covered Recipient Entity Clinnova | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220695489 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,762.50 | 06/30/2025 | Non-covered Recipient Entity Clinnova | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220695491 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,108.30 | 06/30/2025 | Non-covered Recipient Entity Clinnova | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220695493 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $798.20 | 06/30/2025 | Non-covered Recipient Entity Clinnova | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220695495 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,340.00 | 06/30/2025 | Non-covered Recipient Entity Clinnova | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220695497 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $15,685.80 | 06/30/2025 | Non-covered Recipient Entity Clinnova | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220695499 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,922.10 | 06/30/2025 | Non-covered Recipient Entity Clinnova | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220695501 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,470.00 | 06/30/2025 | Non-covered Recipient Entity Clinnova | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220695503 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,340.00 | 06/30/2025 | Non-covered Recipient Entity Clinnova | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220695505 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,632.50 | 06/30/2025 | Non-covered Recipient Entity Clinnova | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220695507 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,470.00 | 06/30/2025 | Non-covered Recipient Entity Clinnova | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220695509 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,340.00 | 06/30/2025 | Non-covered Recipient Entity Clinnova | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220695511 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $798.20 | 06/30/2025 | Non-covered Recipient Entity Clinnova | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220695513 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,678.00 | 06/30/2025 | Non-covered Recipient Entity CLINNOVA RESEARCH SOLUTIONS CORPORA TION | ??A Phase 2b Multicenter, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Moderately to Severely Active Ulcerative Colitis?. ??Efficacy and Safety of JNJ-77242113 in Pa | No dispute reported | 06/30/2026 | 1175421711 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $59.94 | 06/24/2025 | Non-covered Recipient Entity Clinnova | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220695541 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $73.00 | 06/24/2025 | Non-covered Recipient Entity Clinnova | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220695543 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $200.00 | 06/12/2025 | Non-covered Recipient Entity CLINNOVA RESEARCH SOLUTIONS CORPORATION | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184206239 |
| Principal investigator 1 | ABBVIE INC. | $682.50 | 06/11/2025 | Non-covered Recipient Entity CLINNOVA RESEARCH SOLUTIONS | A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease | No dispute reported | 06/30/2026 | 1202490835 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $475.00 | 06/06/2025 | Non-covered Recipient Entity CLINNOVA RESEARCH SOLUTIONS | A PHASE 4 STUDY EVALUATING REAL-WORLD USE OF CDPATH?, A CROHN'S DISEASE RISK PREDICTION TOOL | No dispute reported | 06/30/2026 | 1223280830 |
| Principal investigator 1 | Bausch Health US, LLC | $411.28 | 06/05/2025 | Non-covered Recipient Entity CLINNOVA RESEARCH SOLUTIONS | A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis | No dispute reported | 06/30/2026 | 1224837525 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $798.20 | 05/28/2025 | Non-covered Recipient Entity Clinnova | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220695515 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,470.00 | 05/28/2025 | Non-covered Recipient Entity Clinnova | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220695517 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,340.00 | 05/28/2025 | Non-covered Recipient Entity Clinnova | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220695519 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,238.30 | 05/28/2025 | Non-covered Recipient Entity Clinnova | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220695521 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,108.30 | 05/28/2025 | Non-covered Recipient Entity Clinnova | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220695523 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $798.20 | 05/28/2025 | Non-covered Recipient Entity Clinnova | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220695525 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,171.30 | 05/28/2025 | Non-covered Recipient Entity CLINNOVA RESEARCH SOLUTIONS CORPORATION | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184198873 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $128.26 | 05/27/2025 | Non-covered Recipient Entity Clinnova | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220695529 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $159.84 | 05/27/2025 | Non-covered Recipient Entity Clinnova | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220695531 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $292.00 | 05/27/2025 | Non-covered Recipient Entity Clinnova | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220695533 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $252.20 | 05/27/2025 | Non-covered Recipient Entity Clinnova | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220695535 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.31 | 05/27/2025 | Non-covered Recipient Entity Clinnova | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220695537 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $6.00 | 05/27/2025 | Non-covered Recipient Entity Clinnova | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220695539 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $46.64 | 05/27/2025 | Non-covered Recipient Entity Clinnova | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220695619 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.96 | 05/27/2025 | Non-covered Recipient Entity Clinnova | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220695621 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $401.50 | 05/27/2025 | Non-covered Recipient Entity Clinnova | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220695623 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4.00 | 05/27/2025 | Non-covered Recipient Entity Clinnova | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220695625 |
| Principal investigator 1 | Janssen Research & Development, LLC | $7,534.00 | 05/23/2025 | Non-covered Recipient Entity CLINNOVA RESEARCH SOLUTIONS CORPORA TION | ??A Phase 2b Multicenter, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Moderately to Severely Active Ulcerative Colitis?. ??Efficacy and Safety of JNJ-77242113 in Participants | No dispute reported | 06/30/2026 | 1175421745 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $882.30 | 05/15/2025 | Non-covered Recipient Entity CLINNOVA RESEARCH SOLUTIONS CORPORATION | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184194627 |
| Principal investigator 1 | Bausch Health US, LLC | $4,775.56 | 05/13/2025 | Non-covered Recipient Entity CLINNOVA RESEARCH SOLUTIONS | A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis | No dispute reported | 06/30/2026 | 1224837521 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,359.00 | 05/12/2025 | Non-covered Recipient Entity Clinnova Rsrch Solutions Corp. | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175170397 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,359.00 | 05/12/2025 | Non-covered Recipient Entity Clinnova Rsrch Solutions Corp. | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175170412 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,602.00 | 05/12/2025 | Non-covered Recipient Entity Clinnova Rsrch Solutions Corp. | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175170441 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,602.00 | 05/12/2025 | Non-covered Recipient Entity Clinnova Rsrch Solutions Corp. | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175170456 |
| Principal investigator 1 | Janssen Research & Development, LLC | $184.00 | 05/12/2025 | Non-covered Recipient Entity Clinnova Rsrch Solutions Corp. | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175170511 |
| Principal investigator 1 | Janssen Research & Development, LLC | $184.00 | 05/12/2025 | Non-covered Recipient Entity Clinnova Rsrch Solutions Corp. | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175170543 |
| Principal investigator 1 | Janssen Research & Development, LLC | $184.00 | 05/12/2025 | Non-covered Recipient Entity Clinnova Rsrch Solutions Corp. | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175170559 |
| Principal investigator 1 | Janssen Research & Development, LLC | $184.00 | 05/12/2025 | Non-covered Recipient Entity Clinnova Rsrch Solutions Corp. | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175170630 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,955.00 | 05/12/2025 | Non-covered Recipient Entity Clinnova Rsrch Solutions Corp. | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175170677 |
| Principal investigator 1 | Janssen Research & Development, LLC | $184.00 | 05/12/2025 | Non-covered Recipient Entity Clinnova Rsrch Solutions Corp. | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175170778 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $11,106.03 | 04/30/2025 | Non-covered Recipient Entity TEXAS ARTHRITIS CENTER, PA | A Randomised, Double-blind, Placebo-controlled, Multi-centre Phase 2b Study to Evaluate the Efficacy, Safety and Tolerability of AZD2693 in Participants with Non-cirrhotic Non-alcoholic Steatohepatitis (NASH) with Fibrosis Who Are Carriers of the PNPLA3 rs738409 148M Risk Allele | No dispute reported | 06/30/2026 | 1185552787 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $798.20 | 04/28/2025 | Non-covered Recipient Entity Clinnova | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220695441 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,228.90 | 04/28/2025 | Non-covered Recipient Entity Clinnova | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220695443 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $798.20 | 04/28/2025 | Non-covered Recipient Entity Clinnova | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220695445 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,228.90 | 04/28/2025 | Non-covered Recipient Entity Clinnova | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220695447 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,448.90 | 04/28/2025 | Non-covered Recipient Entity Clinnova | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220695449 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,228.90 | 04/28/2025 | Non-covered Recipient Entity Clinnova | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220695451 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,922.10 | 04/28/2025 | Non-covered Recipient Entity Clinnova | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220695453 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $15,973.10 | 04/28/2025 | Non-covered Recipient Entity Clinnova | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220695455 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $15,685.80 | 04/28/2025 | Non-covered Recipient Entity Clinnova | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220695457 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $13,646.10 | 04/28/2025 | Non-covered Recipient Entity Clinnova | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220695459 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $9,535.50 | 04/28/2025 | Non-covered Recipient Entity Clinnova | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220695461 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,632.50 | 04/28/2025 | Non-covered Recipient Entity Clinnova | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220695463 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,762.50 | 04/28/2025 | Non-covered Recipient Entity Clinnova | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220695465 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,358.90 | 04/28/2025 | Non-covered Recipient Entity Clinnova | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220695467 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,228.90 | 04/28/2025 | Non-covered Recipient Entity Clinnova | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220695471 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $11,359.40 | 04/28/2025 | Non-covered Recipient Entity Clinnova | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220695473 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,581.00 | 04/28/2025 | Non-covered Recipient Entity CLINNOVA RESEARCH SOLUTIONS CORPORATION | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184190759 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $175.00 | 04/28/2025 | Non-covered Recipient Entity CLINNOVA RESEARCH SOLUTIONS CORPORATION | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184190761 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $155.00 | 04/28/2025 | Non-covered Recipient Entity CLINNOVA RESEARCH SOLUTIONS CORPORATION | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184190763 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $151.32 | 04/23/2025 | Non-covered Recipient Entity Clinnova | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220695527 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $19.98 | 04/23/2025 | Non-covered Recipient Entity Clinnova | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220695615 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $36.50 | 04/23/2025 | Non-covered Recipient Entity Clinnova | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220695617 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4.50 | 04/22/2025 | Non-covered Recipient Entity Clinnova | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220695469 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4.50 | 04/22/2025 | Non-covered Recipient Entity Clinnova | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220695475 |
| Principal investigator 1 | Janssen Research & Development, LLC | $50.00 | 04/21/2025 | Non-covered Recipient Entity CLINNOVA RESEARCH SOLUTIONS CORPORA TION | ??A Phase 2b Multicenter, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Moderately to Severely Active Ulcerative Colitis?. ??Efficacy and Safety of JNJ-77242113 in Participants | No dispute reported | 06/30/2026 | 1175421750 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $475.00 | 04/09/2025 | Non-covered Recipient Entity CLINNOVA RESEARCH SOLUTIONS | A PHASE 4 STUDY EVALUATING REAL-WORLD USE OF CDPATH?, A CROHN'S DISEASE RISK PREDICTION TOOL | No dispute reported | 06/30/2026 | 1223277678 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,171.30 | 04/01/2025 | Non-covered Recipient Entity CLINNOVA RESEARCH SOLUTIONS CORPORATION | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184180824 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,406.00 | 03/31/2025 | Non-covered Recipient Entity CLINNOVA RESEARCH SOLUTIONS CORPORA TION | ??A Phase 2b Multicenter, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Moderately to Severely Active Ulcerative Colitis?. ??Efficacy and Safety of JNJ-77242113 in Participants | No dispute reported | 06/30/2026 | 1175421733 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,922.10 | 03/27/2025 | Non-covered Recipient Entity Clinnova | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220695425 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $15,685.80 | 03/27/2025 | Non-covered Recipient Entity Clinnova | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220695427 |
| Principal investigator 1 | Eli Lilly and Company | $29,899.80 | 03/26/2025 | Non-covered Recipient Entity CLINNOVA RESEARCH SOLUTIONS CORPORATION | AN ADAPTIVE, DOSE-RANGING, PHASE 2 STUDY OF ELTREKIBART GIVEN ALONE OR IN COMBINATION WITH MIRIKIZUMAB FOR THE TREATMENT OF ADULT PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS | No dispute reported | 06/30/2026 | 1187883122 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $79.92 | 03/25/2025 | Non-covered Recipient Entity Clinnova | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220695439 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $438.00 | 03/25/2025 | Non-covered Recipient Entity Clinnova | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220695611 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2.00 | 03/25/2025 | Non-covered Recipient Entity Clinnova | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220695613 |
| Principal investigator 1 | Celgene Corporation | $5,000.00 | 03/25/2025 | Non-covered Recipient Entity Clinnova Research Solutions | A Phase 3, Multicenter, Open-Label Extension Study of Oral Ozanimod for Moderately to Severely Active Crohns Disease | No dispute reported | 06/30/2026 | 1222306587 |
| Principal investigator 1 | Bausch Health US, LLC | $5,854.97 | 03/11/2025 | Non-covered Recipient Entity CLINNOVA RESEARCH SOLUTIONS | A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis | No dispute reported | 06/30/2026 | 1224837513 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,053.60 | 03/11/2025 | Non-covered Recipient Entity CLINNOVA RESEARCH SOLUTIONS CORPORATION | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184170880 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,728.00 | 03/06/2025 | Non-covered Recipient Entity CLINNOVA RESEARCH SOLUTIONS CORPORA TION | ??A Phase 2b Multicenter, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Moderately to Severely Active Ulcerative Colitis?. ??Efficacy and Safety of JNJ-77242113 in Participants | No dispute reported | 06/30/2026 | 1175421683 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $175.00 | 03/04/2025 | Non-covered Recipient Entity CLINNOVA RESEARCH SOLUTIONS CORPORATION | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184156742 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $45.00 | 03/04/2025 | Non-covered Recipient Entity CLINNOVA RESEARCH SOLUTIONS CORPORATION | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184156744 |
| Principal investigator 1 | Janssen Research & Development, LLC | $335.00 | 02/26/2025 | Non-covered Recipient Entity Clinnova Rsrch Solutions Corp. | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175170428 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,602.00 | 02/26/2025 | Non-covered Recipient Entity Clinnova Rsrch Solutions Corp. | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175170461 |
| Principal investigator 1 | Janssen Research & Development, LLC | $184.00 | 02/26/2025 | Non-covered Recipient Entity Clinnova Rsrch Solutions Corp. | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175170475 |
| Principal investigator 1 | Janssen Research & Development, LLC | $184.00 | 02/26/2025 | Non-covered Recipient Entity Clinnova Rsrch Solutions Corp. | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175170501 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,955.00 | 02/26/2025 | Non-covered Recipient Entity Clinnova Rsrch Solutions Corp. | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175170518 |
| Principal investigator 1 | Janssen Research & Development, LLC | $335.00 | 02/26/2025 | Non-covered Recipient Entity Clinnova Rsrch Solutions Corp. | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175170624 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,955.00 | 02/26/2025 | Non-covered Recipient Entity Clinnova Rsrch Solutions Corp. | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175170671 |
| Principal investigator 1 | Janssen Research & Development, LLC | $184.00 | 02/26/2025 | Non-covered Recipient Entity Clinnova Rsrch Solutions Corp. | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175170692 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,602.00 | 02/26/2025 | Non-covered Recipient Entity Clinnova Rsrch Solutions Corp. | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175170708 |
| Principal investigator 1 | Janssen Research & Development, LLC | $184.00 | 02/26/2025 | Non-covered Recipient Entity Clinnova Rsrch Solutions Corp. | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175170722 |
| Principal investigator 1 | Janssen Research & Development, LLC | $184.00 | 02/26/2025 | Non-covered Recipient Entity Clinnova Rsrch Solutions Corp. | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175170730 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,359.00 | 02/26/2025 | Non-covered Recipient Entity Clinnova Rsrch Solutions Corp. | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175170748 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $104.94 | 02/25/2025 | Non-covered Recipient Entity Clinnova | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220695433 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $328.50 | 02/25/2025 | Non-covered Recipient Entity Clinnova | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220695435 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $5.00 | 02/25/2025 | Non-covered Recipient Entity Clinnova | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220695437 |
| Principal investigator 1 | Janssen Research & Development, LLC | $50.00 | 02/24/2025 | Non-covered Recipient Entity CLINNOVA RESEARCH SOLUTIONS CORPORA TION | ??A Phase 2b Multicenter, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Moderately to Severely Active Ulcerative Colitis?. ??Efficacy and Safety of JNJ-77242113 in Participants | No dispute reported | 06/30/2026 | 1175421660 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $5,823.90 | 02/18/2025 | Non-covered Recipient Entity CLINNOVA RESEARCH SOLUTIONS CORPORATION | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184154210 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $45.00 | 02/18/2025 | Non-covered Recipient Entity CLINNOVA RESEARCH SOLUTIONS CORPORATION | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184154212 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $122.60 | 02/18/2025 | Non-covered Recipient Entity CLINNOVA RESEARCH SOLUTIONS CORPORATION | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184154214 |
| Principal investigator 1 | Janssen Research & Development, LLC | $672.00 | 02/17/2025 | Non-covered Recipient Entity CLINNOVA RESEARCH SOLUTIONS CORPORA TION | ??A Phase 2b Multicenter, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Moderately to Severely Active Ulcerative Colitis?. ??Efficacy and Safety of JNJ-77242113 in Participants | No dispute reported | 06/30/2026 | 1175421701 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $7,910.95 | 02/05/2025 | Non-covered Recipient Entity CLINNOVA RESEARCH SOLUTIONS CORPORATION | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184152458 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $42,096.59 | 01/31/2025 | Non-covered Recipient Entity CLINNOVA RESEARCH SOLUTIONS | A Randomised, Double-blind, Placebo-controlled, Multi-centre Phase 2b Study to Evaluate the Efficacy, Safety and Tolerability of AZD2693 in Participants with Non-cirrhotic Non-alcoholic Steatohepatitis (NASH) with Fibrosis Who Are Carriers of the PNPLA3 rs738409 148M Risk Allele | No dispute reported | 06/30/2026 | 1185552785 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,678.00 | 01/31/2025 | Non-covered Recipient Entity CLINNOVA RESEARCH SOLUTIONS CORPORA TION | ??A Phase 2b Multicenter, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Moderately to Severely Active Ulcerative Colitis?. ??Efficacy and Safety of JNJ-77242113 in Participants | No dispute reported | 06/30/2026 | 1175421717 |
| Principal investigator 1 | ABBVIE INC. | $11,000.00 | 01/28/2025 | Non-covered Recipient Entity CLINNOVA RESEARCH SOLUTIONS | M23-784 - A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease | No dispute reported | 06/30/2026 | 1202441610 |
| Principal investigator 1 | ABBVIE INC. | $9,250.00 | 01/28/2025 | Non-covered Recipient Entity CLINNOVA RESEARCH SOLUTIONS | M23-784 - A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease | No dispute reported | 06/30/2026 | 1202441613 |
| Principal investigator 1 | Bausch Health US, LLC | $1,262.39 | 01/28/2025 | Non-covered Recipient Entity CLINNOVA RESEARCH SOLUTIONS | A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis | No dispute reported | 06/30/2026 | 1224837509 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $59.94 | 01/27/2025 | Non-covered Recipient Entity Clinnova | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220695429 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $255.50 | 01/27/2025 | Non-covered Recipient Entity Clinnova | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220695431 |
| Principal investigator 1 | Bausch Health US, LLC | $411.28 | 01/13/2025 | Non-covered Recipient Entity CLINNOVA RESEARCH SOLUTIONS | A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis | No dispute reported | 06/30/2026 | 1224837517 |
| Principal investigator 1 | Celgene Corporation | $705.16 | 01/01/2025 | Non-covered Recipient Entity OC Gastrocare | Induction Study #1 - A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohns Disease | No dispute reported | 06/30/2026 | 1222306677 |